Magni, Lara
Yu, Haoran
Christensen, Nynne M.
Poulsen, Mette H.
Frueh, Alexander
Deshar, Ganga
Johansen, Astrid Z.
Johansen, Julia S.
Pless, Stephan A.
Jørgensen, Niklas R.
Novak, Ivana
Funding for this research was provided by:
Marie Skłodowska-Curie COFUND Doctoral Programme TALENT (grant number H2020-MSCA-COFUND-2017-801199, grant number H2020-MSCA-COFUND-2017-801199)
Sundhed og Sygdom, Det Frie Forskningsråd (8020-00254B)
Copenhagen University
Article History
Received: 16 February 2024
Accepted: 18 April 2024
First Online: 25 April 2024
Declarations
:
: All procedures involving patients and patient materials were approved by the Danish Ethics Committee. The Danish BIOPAC study “BIOmarkers in patients with PAncreatic Cancer (BIOPAC) - can they provide new information of the disease and improve diagnosis and prognosis of the patients?” (ClinicalTrials.gov ID: NCT03311776; () was approved by the Danish Ethics Committee (VEK, j.nr. KA-20060113) and the Danish Data Protection Agency (j.nr. 2012-58-0004; HGH-2015-027; I-Suite j.nr. 03960; and PACTICUS P-2020-834). The Danish Osteoporosis Prevention Study DOPS was approved by the Danish Ethics Committee (j.nr. 1990/1821).
: Not applicable.
: The authors declare no competing interests.